Quoin pharmaceuticals announces additional positive ‘whole body' clinical data from ongoing pediatric netherton syndrome study and approval to initiate testing of a second pediatric patient

Ashburn, va., april 02, 2025 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing investigator pediatric netherton syndrome (ns) study. after 6 weeks of continued whole body application of qrx003, the subject's skin remains almost completely healed demonstrating the durability of ongoing daily treatment with the product. in addition, the patient has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids. importantly, with the patient's pruritus or itch almost completely eliminated, she continues to experience zero nightly sleep disturbances without the need for any sedating medication, marking the first continuous period of uninterrupted sleep in the patient's life. no adverse events have been reported to date after 6 weeks of whole body treatment with qrx003.
QNRX Ratings Summary
QNRX Quant Ranking